

IN THE CLAIMS

The status of each claim of the present application is listed below.

Claims 1-29: Canceled.

30. (New) A process for preparing a monoclonal antibody, comprising:
rendering an animal tolerant to an eukaryotic cell in a first state;
detecting said tolerant animal;
immunizing said tolerant animal, by injection of the eukaryotic cell in a second state
carrying a neo-antigen or a non-self antigen;
fusing B cells of said immunized mice with a myeloma cell line; and
selecting (1) a hybridoma which secretes an antibody having the same epitope
specificity as the antibody produced by hybridoma Pf 26G1/B4 deposited at Collection
Nationale de Cultures de Microorganismes (CNCM) on February 23, 2001, under accession
number I-2635 or (2) a hybridoma which secretes an antibody having the same epitope
specificity as the antibody produced by hybridoma Pf 26G1/C10 deposited at Collection
Nationale de Cultures de Microorganismes (CNCM) on February 23, 2001, under accession
number I-2636.

31. (New) The process of Claim 30, wherein (1) is selected.

32. (New) The process of Claim 30, wherein (2) is selected.

33. (New) The process of Claim 30, further comprising culturing the selected
hybridoma and purifying the monoclonal antibody.

34. (New) The process of Claim 30, wherein the antibody is further humanized.

35. (New) A process of Claim 30, wherein the animal is a mouse.

36. (New) The process of Claim 30, wherein the antibody is produced by hybridoma Pf 26G1/B4 deposited at Collection Nationale de Cultures de Microorganismes (CNCM) on February 23, 2001, under accession number I-2635

37. (New) The process of Claim 30, wherein the antibody is produced by hybridoma Pf 26G1/C10 deposited at Collection Nationale de Cultures de Microorganismes (CNCM) on February 23, 2001, under accession number I-2636.

38. (New) A process for selecting a native or conformational antigen, comprising:
preparing a monoclonal antibody according to the process of Claim 30;
contacting the monoclonal antibody with an antigenic preparation; and
selecting the complex formed between the monoclonal antibody and the
conformational native antigen of interest.

39. (New) The process of Claim 38, further comprising:
revealing the complex; and
optionally, separating the antibody from the conformational antigen from the
complex.

SUPPORT FOR THE AMENDMENT

Claims 1-29 have been canceled in favor of Claim 30-39. Newly-added Claims 30-39 are supported by the specification at pages 3-23 and original Claims 1-29. Accordingly, no new matter is believed to have been added to the present application by entry of this amendment.